The laboratory of Ronald DeMatteo is focused on developing strategies to reduce immune subversion in gastrointestinal stromal tumor and liver cancer and on immunobiology in liver cancer.
Ronald DeMatteo, MD
Research FocusPhysician-scientist Ronald DeMatteo focuses on strategies to reduce immune subversion in gastrointestinal stromal tumor and liver cancer and on immunobiology in liver cancer.
- Balachandran VP, Cavnar MJ, Zeng S, Bamboat ZM, Ocuin LM, Obaid H, Sorenson EC, Popow R, Ariyan C, Rossi F, Besmer P, Guo T, Antonescu CR, Taguchi T, Yuan J, Wolchok JD, Allison JP, DeMatteo RP. Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido. Nat Med. 2011 Aug 28;17(9):1094-100. doi: 10.1038/nm.2438.
- Bamboat ZM, Ocuin LM, Balachandran VP, Obaid H, Plitas G, DeMatteo RP. Conventional DCs reduce liver ischemia/reperfusion injury in mice via IL-10 secretion. J Clin Invest. 2010 Feb;120(2):559-69. doi: 10.1172/JCI40008. Epub 2010 Jan 19.
- Discovery that the effect of imatinib in GIST partially depends on inhibition of the immunosuppressive enzyme indoleamine 2,3-dioxygenase (IDO), and the combination of ipilimumab and imatinib was synergistic in a mouse model, insights that became the basis for an NCI-sponsored phase I clinical trial in advanced GIST
- Development of an online nomogram to estimate the individual risk of recurrence following resection of primary GIST
- Randomized phase III trial showing that adjuvant imatinib prolongs recurrence-free survival following the resection of primary GIST, which led to FDA approval of the use of adjuvant imatinib
- Discovery that toll-like receptor 9 (TLR9) mediates protection from liver ischemia/reperfusion injury, and part of the mechanism depends on TLR9-mediated production of IL-10 in conventional dendritic cells
- Discovery that inhibition of toll-like receptor 9 (TLR9) reduces sepsis in mice